

HALOZYME THERAPEUTICS INC

Form 4

June 25, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
KIRK RANDAL J

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS INC [HALO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2008

Director 10% Owner
 Officer (give title below) Other (specify below)

1881 GROVE AVENUE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

RADFORD, VA 24141

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock					370,000	D	
Common Stock					2,189,050	I	by 2000LP ⁽¹⁾
Common Stock					3,000,000	I	by Radford ⁽¹⁾
Common Stock					135,000	I	by Staff 2001 ⁽¹⁾
Common Stock					1,326,320	I	by NRM IV ⁽¹⁾

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock						522,460	I	by RJK ⁽¹⁾
Common Stock						6,328,853	I	by NRM V ⁽¹⁾
Common Stock	06/23/2008	P	427,100	A	\$ 5.93	985,291	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	3,080	A	\$ 5.84	988,371	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	7,000	A	\$ 5.83	995,371	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	1,200	A	\$ 5.82	996,571	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	1,300	A	\$ 5.81	997,871	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	6,220	A	\$ 5.8	1,004,091	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	1,200	A	\$ 5.79	1,005,291	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	5,000	A	\$ 5.78	1,010,291	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	1,496	A	\$ 5.72	1,011,787	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	23,504	A	\$ 5.71	1,035,291	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	24,100	A	\$ 5.7	1,059,391	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	6,400	A	\$ 5.69	1,065,791	I	by Kirkfield ⁽¹⁾
Common Stock	06/23/2008	P	6,700	A	\$ 5.68	1,072,491	I	by Kirkfield ⁽¹⁾

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	06/23/2008		P	10,808	A	\$ 5.67	1,083,299	I	by Kirkfield (1)
Common Stock	06/23/2008		P	9,800	A	\$ 5.66	1,093,099	I	by Kirkfield (1)
Common Stock	06/23/2008		P	13,092	A	\$ 5.65	1,106,191	I	by Kirkfield (1)
Common Stock	06/23/2008		P	136,761	A	\$ 5.64	1,242,952	I	by Kirkfield (1)
Common Stock	06/23/2008		P	9,100	A	\$ 5.63	1,252,052	I	by Kirkfield (1)
Common Stock	06/23/2008		P	10,400	A	\$ 5.62	1,262,452	I	by Kirkfield (1)
Common Stock	06/23/2008		P	4,200	A	\$ 5.61	1,266,652	I	by Kirkfield (1)
Common Stock	06/23/2008		P	4,271	A	\$ 5.6	1,270,923	I	by Kirkfield (1)
Common Stock	06/23/2008		P	300	A	\$ 5.59	1,271,223	I	by Kirkfield (1)
Common Stock	06/23/2008		P	200	A	\$ 5.58	1,271,423	I	by Kirkfield (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
--	--	--------------------------------------	--	--------------------------------	---	--	---

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	\$ 1.75	06/23/2008	P				(2)	01/28/2009	Common Stock	136,300

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KIRK RANDAL J 1881 GROVE AVENUE RADFORD, VA 24141	X	X		

Signatures

/s/ Randal J. Kirk
Date: 06/25/2008

**Signature of Reporting Person
Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 Randal J. Kirk controls each of Randal J. Kirk (2000) Limited Partnership ("2000LP"), RJK, L.L.C. ("RJK"), Radford Investments Limited Partnership ("Radford"), Third Security Staff 2001 LLC ("Staff 2001"), New River Management IV, LP ("NRM IV"), New River Management V, LP ("NRM V") and Kirkfield, L.L.C. ("Kirkfield"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.
- (1) These warrants are immediately exercisable.
- (2) These warrants are immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.